BiotechTube

piclozotan low dose + placebo + piclozotan high dose

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stroke

Conditions

Stroke

Trial Timeline

Sep 1, 2004 → Jan 1, 2007

NCT ID
NCT00272909

About piclozotan low dose + placebo + piclozotan high dose

piclozotan low dose + placebo + piclozotan high dose is a phase 2 stage product being developed by Daiichi Sankyo for Stroke. The current trial status is terminated. This product is registered under clinical trial identifier NCT00272909. Target conditions include Stroke.

What happened to similar drugs?

13 of 20 similar drugs in Stroke were approved

Approved (13) Terminated (6) Active (4)
✅StatinShionogiApproved
✅AlteplaseKyowa KirinApproved
✅RepathaAmgenApproved
✅DonepezilPfizerApproved
✅Oral Anticoagulant + Antiplatelet DrugPfizerApproved
✅Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)Mochida PharmaceuticalApproved
✅Clopidogrel + Clopidogrel placebo + AspirinBristol Myers SquibbApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00272909Phase 2Terminated

Competing Products

20 competing products in Stroke

See all competitors
ProductCompanyStageHype Score
SPT-07A injectionSinopharmPhase 3
36
Osmotic drugsSinopharmPre-clinical
33
Aspirin, ClopidogrelYuhanPre-clinical
26
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
32
SUN13837 + placeboDaiichi SankyoPhase 2
27
DS-1040b + AspirinDaiichi SankyoPhase 1
29
DS1040b + PlaceboDaiichi SankyoPre-clinical
26
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
35
warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxabanDaiichi SankyoPhase 3
40
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
35
ASP2246Astellas PharmaPhase 1/2
39
Neu2000KWL + Neu2000KWL + Neu2000KWL + PlacebosSun PharmaceuticalPhase 2
35
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
31
Redasemtide + PlaceboShionogiPhase 2
39
StatinShionogiApproved
43
AlteplaseKyowa KirinApproved
43
ONO-2506 + ONO-2506 + ONO-2506Ono PharmaceuticalPhase 2/3
38
AbciximabEli LillyPhase 3
32
AbciximabEli LillyPhase 3
32
SB623 Implant (2.5M) + SB623 Implant (5.0M)Sumitomo PharmaPhase 2
35